Patients characteristics of patients with heart failure between 2002 and 2015
| Overall | 2002–2005 | 2006–2008 | 2009–2012 | 2013–2015 | % missing | |
| n | 85 732 | 25 366 | 17 715 | 26 114 | 16 537 | |
| Demographics | ||||||
| Age (years, median (IQR)) | 79.1(70.2, 85.7) | 78.7(70.7, 84.9) | 78.7(69.9, 85.4) | 79.5(70.1, 86.3) | 79.7(70.0, 86.4) | 0 |
| Sex (% women) | 48.6 | 49.3 | 48.4 | 48.4 | 48.0 | 0 |
| Ethnicity (% Caucasian) | 96.5 | 97.5 | 96.9 | 96.1 | 95.1 | 3.5 |
| Social deprivation* (% lowest quintile) | 24.3 | 25.1 | 25.0 | 24.0 | 22.9 | 0 |
| Clinical and lifestyle measurements | ||||||
| SBP (mm Hg, mean (SD)) | 136.2 (20.7) | 140.6 (22.3) | 135.9 (20.7) | 134.6 (20.0) | 132.9 (18.7) | 13.0 |
| DBP (mm Hg, mean (SD)) | 76.2 (12.0) | 78.4 (12.0) | 76.2 (12.0) | 75.4 (12.0) | 74.4 (11.6) | 13.0 |
| BMI (kg/m2, mean (SD)) | 28.6 (6.6) | 28.2 (6.4) | 28.4 (6.6) | 28.7 (6.8) | 28.8 (6.8) | 54.0 |
| eGFR (min/m2/1.73 mL, median (IQR)) | 58.4(45.3, 72.1) | 54.7(43.4, 66.1) | 56.5(44.3, 68.8) | 60.5(46.3, 75.3) | 62.9(47.5, 78.2) | 24.0 |
| Smoking status (% current) | 20.8 | 22.3 | 20.0 | 20.4 | 20.5 | 38.7 |
| Medical history (%)†‡ | ||||||
| Atrial fibrillation | 36.6 | 28.4 | 36.3 | 40.6 | 43.0 | – |
| COPD | 17.9 | 14.8 | 17.3 | 19.5 | 21.0 | – |
| Diabetes | 22.3 | 18.1 | 22.2 | 23.7 | 26.7 | – |
| Hypertension | 60.7 | 46.0 | 60.7 | 67.9 | 72.0 | – |
| Ischaemic heart disease | 44.2 | 39.0 | 46.0 | 46.4 | 46.8 | – |
| Valvular disease | 16.5 | 9.5 | 14.9 | 19.9 | 23.8 | – |
| Medication prescription up to 3 months after HF diagnosis (%)‡ | ||||||
| RAS inhibitors | 60.8 | 59.6 | 63.5 | 62.0 | 57.6 | – |
| Beta blockers | 42.5 | 28.9 | 41.0 | 49.3 | 54.1 | – |
| MR-antagonists | 18.0 | 18.4 | 17.9 | 17.6 | 18.2 | – |
| Loop diuretics | 63.0 | 68.4 | 63.5 | 61.1 | 57.0 | – |
*Assessed by index of multiple deprivation.
†Denotes prior medical history of given comorbidity.
‡Medical conditions and prescriptions were considered absent if not recorded.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; CPRD, clinical practice research datalink; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; MR, mineralocorticoid receptor; RAS inhibitors, angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers; SBP, systolic blood pressure.